291. ヒルシュスプルング病（全結腸型又は小腸型） Hirschsprung disease, entire colon type Clinical trials / Disease details
臨床試験数 : 12 / 薬物数 : 24 - (DrugBank : 15) / 標的遺伝子数 : 0 - 標的パスウェイ数 : 0
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | JPRN-UMIN000024993 | 2016/12/01 | 15/12/2016 | Study for efficacy of usage of enteral nutrient with immuno-balance modulation action in perioperative management of pediatric patients | Study for efficacy of usage of enteral nutrient with immuno-balance modulation action in perioperative management of pediatric patients - Efficacy in usage of enteral nutrient with immuno-balance modulation action | Hirschsprung's disease, Atresia ani, Congenital biliary dilatation, GERD | In the control group, the following enteral nutrient will be administered (breast milk or artificial milk for infants, Racol for infants). Dose and duration: Before surgery, the patient will take enteral nutrients at 60 to 100 kcal / kg per day for 3 days. After the surgery, enteral nutrition will restart within 2 to 3 days after surgery, and continue until 6th postoperative day. In contrast, immunomodulatory nutrition is administered in the test group. Dose and duration: Before surgery, the patient will take enteral nutrients at 60 to 100 kcal / kg per day for 3 days. After the surgery, enteral nutrition will restart within 2 to 3 days after surgery, and continue until 6th postoperative day. The study period is from December 1, 2016 to March 31, 2018. | University of Tsukuba Hospital | NULL | Pending | 6months-old | 48months-old | Male and Female | 10 | Not applicable | Japan |